Health analytics

Our health and the challenges healthcare systems face are changing. Patients have increasingly complex health needs owing to multimorbidity, and they experience large inequalities in healthcare outcomes. Meanwhile, the assessment of medicines and corresponding payment mechanisms do not reflect the true value that good health brings to healthcare systems and wider society.

With our innovative and market-leading analytics, we aim to enable the transition of health systems from importers of illness to exporters of health by realigning value between patients, manufacturers of medicines, and payers.

How the life sciences sector can address the greatest health challenges and reduce inequalities

Health is one of our most untapped opportunities for prosperity and happiness, as both individuals and society. Yet these opportunities are not shared equally. The life sciences sector has a unique opportunity to actively reduce health inequalities, which we explore in our report.

Explore the report
ONS Health Index Explorer

See the health index in your area, how it has changed over time and compares to other local authorities.

Start here
Going swimmingly or treading water?

Read our on point paper which explores whether the elective recovery plan is bringing down NHS waiting lists.

Read the report
NHS waiting list tracker

Explore our interactive tracker to see how waiting lists for NHS services vary across England.

Start here

Shifting health systems from importers of illness to exporters of health

Combining strategic vision with innovative analytics

We work with clients in the life sciences and healthcare industries, combining our strategic vision with innovative and market leading analytics to support three key transitions:

Moving from single disease focus to holistic assessment of healthcare need, through unmasking increasingly complex, multimorbid, unmet patient needs, to informing targeted action, and improving health equity.
A broader value of medicines and health; re-aligning how health technology assessment bodies and governments value medicines and the value of health to patients, populations, and economies.
Improving health equity by embedding consideration of inequalities across the medicine life cycle.

Long exposure lights of cars driving along a snaking road

Delivering integrated insights that add the most value

We combine our expertise across our service areas to deliver integrated insights that add the most value for our clients. We support clients across the entire innovation lifecycle by:

Using real-world healthcare data to meet evidence generation needs for payers and regulators. Payers are those, other than patients, who cover the cost of medicines such as the NHS in the UK.
Applying scientific rigour when evaluating the economic and clinical value of healthcare interventions to enable patient access.
Developing holistic strategies for market access and real-world evidence needs to drive commercial success.
Creating integrated and compelling visual analytics, powered by AI, to support engagement with medical, scientific and policy leaders.
Leveraging large-scale human omics data and cutting-edge analytical techniques to improve the speed and cost-efficiency of drug development.

At LCP we are more than just a service provider – we are your strategic thought partner

We will work with clients from pitch to delivery, with hands-on project leadership by senior experts across service areas. Our leadership experience in science, medicine, consulting, pharmaceuticals and policy, and our partnerships with key decision makers, combined with our state-of-the-art technology, methods and expertise, mean we provide insights to tackle the challenges of tomorrow.

Contact us to learn more about how we can bring you clarity and insight in an increasingly complex life sciences and healthcare environment.

Explore our focus areas

Health equity

Obesity

Until now there has been limited research on the impact of multi and co-morbidities across different patient groups and how this progresses during the course of the disease. This study has highlighted the large variations in clinical need within the patient group.

Programme director, Data and Real World Evidence National Institute for Health and Care Excellence (NICE)